What was the overall market valuation for the US parry romberg-syndrome market in 2024?

The overall market valuation for the US parry romberg-syndrome market was $52.5 Million in 2024. Read More

What is the projected market valuation for the US parry romberg-syndrome market by 2035?

The projected market valuation for the US parry romberg-syndrome market is $107.09 Million by 2035. Read More

What is the expected CAGR for the US parry romberg-syndrome market during the forecast period 2025 - 2035?

The expected CAGR for the US parry romberg-syndrome market during the forecast period 2025 - 2035 is 6.7%. Read More

Which companies are considered key players in the US parry romberg-syndrome market?

Key players in the US parry romberg-syndrome market include Bristol-Myers Squibb, Novartis, Pfizer, Roche, Sanofi, Merck & Co, AstraZeneca, Johnson & Johnson, and GSK. Read More

What are the treatment type segment valuations for the US parry romberg-syndrome market?

The treatment type segment valuations include Medication at $15.75 - $31.5 Million, Surgery at $10.5 - $21.0 Million, Physical Therapy at $13.5 - $27.0 Million, and Psychological Support at $12.75 - $25.5 Million. Read More

What are the diagnosis method segment valuations for the US parry romberg-syndrome market?

The diagnosis method segment valuations include Clinical Evaluation at $20.0 - $40.0 Million, Imaging Techniques at $15.0 - $30.0 Million, Biopsy at $10.0 - $20.0 Million, and Genetic Testing at $7.5 - $17.09 Million. Read More

How does the patient age group segment break down in the US parry romberg-syndrome market?

The patient age group segment includes Children at $10.5 - $21.0 Million, Adolescents at $12.0 - $24.0 Million, and Adults at $30.0 - $62.09 Million. Read More

What are the care setting segment valuations for the US parry romberg-syndrome market?

The care setting segment valuations include Hospital at $20.0 - $40.0 Million, Specialty Clinic at $15.0 - $30.0 Million, and Home Care at $17.5 - $37.09 Million. Read More

What trends are expected in the US parry romberg-syndrome market by 2035?

By 2035, the US parry romberg-syndrome market is expected to experience growth driven by advancements in treatment options and increased awareness. Read More

What factors may influence the growth of the US parry romberg-syndrome market during the forecast period?

Factors influencing growth may include ongoing research, the introduction of innovative therapies, and enhanced diagnostic methods. Read More

US Parry-Romberg Syndrome Market

ID: MRFR/Pharma/18459-HCR

100 Pages

Satyendra Maurya

Last Updated: May 13, 2026

US Parry Romberg Syndrome Market Research Report By Diagnosis (Physical Examination, MRI Scan, Serum Test, others), By Treatment (Drug Treatment, Surgery, others) and By End User (Hospitals & Clinics, Physical Therapists, others) - Growth & Industry Forecast 2025 To 2035

US Parry-Romberg Syndrome Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Medical Device, BY Treatment Type (USD Million) | |
  1. 4.1.1 Medication | |
  2. 4.1.2 Surgery | |
  3. 4.1.3 Physical Therapy | |
  4. 4.1.4 Psychological Support |
2. 4.2 Medical Device, BY Diagnosis Method (USD Million) | |
  1. 4.2.1 Clinical Evaluation | |
  2. 4.2.2 Imaging Techniques | |
  3. 4.2.3 Biopsy | |
  4. 4.2.4 Genetic Testing |
3. 4.3 Medical Device, BY Patient Age Group (USD Million) | |
  1. 4.3.1 Children | |
  2. 4.3.2 Adolescents | |
  3. 4.3.3 Adults |
4. 4.4 Medical Device, BY Care Setting (USD Million) | |
  1. 4.4.1 Hospital | |
  2. 4.4.2 Specialty Clinic | |
  3. 4.4.3 Home Care 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Medical Device | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Bristol-Myers Squibb (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Novartis (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Pfizer (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Roche (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Sanofi (FR) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Merck & Co (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 AstraZeneca (GB) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Johnson & Johnson (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 GSK (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE |
6. 6.3 US MARKET ANALYSIS BY DIAGNOSIS METHOD |
7. 6.4 US MARKET ANALYSIS BY PATIENT AGE GROUP |
8. 6.5 US MARKET ANALYSIS BY CARE SETTING |
9. 6.6 KEY BUYING CRITERIA OF MEDICAL DEVICE |
10. 6.7 RESEARCH PROCESS OF MRFR |
11. 6.8 DRO ANALYSIS OF MEDICAL DEVICE |
12. 6.9 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE |
13. 6.10 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE |
14. 6.11 SUPPLY / VALUE CHAIN: MEDICAL DEVICE |
15. 6.12 MEDICAL DEVICE, BY TREATMENT TYPE, 2024 (% SHARE) |
16. 6.13 MEDICAL DEVICE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million) |
17. 6.14 MEDICAL DEVICE, BY DIAGNOSIS METHOD, 2024 (% SHARE) |
18. 6.15 MEDICAL DEVICE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million) |
19. 6.16 MEDICAL DEVICE, BY PATIENT AGE GROUP, 2024 (% SHARE) |
20. 6.17 MEDICAL DEVICE, BY PATIENT AGE GROUP, 2024 TO 2035 (USD Million) |
21. 6.18 MEDICAL DEVICE, BY CARE SETTING, 2024 (% SHARE) |
22. 6.19 MEDICAL DEVICE, BY CARE SETTING, 2024 TO 2035 (USD Million) |
23. 6.20 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
24. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
25. 7.2 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million) | |
  2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million) | |
  3. 7.2.3 BY PATIENT AGE GROUP, 2025-2035 (USD Million) | |
  4. 7.2.4 BY CARE SETTING, 2025-2035 (USD Million) |
26. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.3.1 |
27. 7.4 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

US Medical Device Market Segmentation

Medical Device By Treatment Type (USD Million, 2025-2035)

Medication
Surgery
Physical Therapy
Psychological Support

Medical Device By Diagnosis Method (USD Million, 2025-2035)

Clinical Evaluation
Imaging Techniques
Biopsy
Genetic Testing

Medical Device By Patient Age Group (USD Million, 2025-2035)

Children
Adolescents
Adults

Medical Device By Care Setting (USD Million, 2025-2035)

Hospital
Specialty Clinic
Home Care

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓